Form 4: Brainstorm Cell Therapeutics Executive Receives Stock Awards

Uri Yablonka, EVP & Chief Business Officer of Brainstorm Cell Therapeutics, received stock awards and restricted stock units on January 1, 2025.

Summary

• Uri Yablonka, an executive at Brainstorm Cell Therapeutics, received 40,000 shares of restricted stock and 20,000 restricted stock units (RSUs) on January 1, 2025.
• The restricted stock vests in two tranches: 50% after six months and the remaining 50% after eighteen months from the grant date, contingent upon continued employment.
• The RSUs vest in two tranches: 50% immediately and the remaining 50% after six months from the grant date, contingent upon continued employment.
• The filing also reflects a 1-for-15 reverse stock split that took place on October 1, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock awards, which is a common practice. The vesting schedule provides some positive incentive for the executive.

Positives

• The grant of restricted stock and RSUs to a key executive suggests an incentive to remain with the company and contribute to its success.

Industry Context

Stock awards are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock awards and RSU grants are standard compensation practices in the biotech industry, often used to attract and retain key personnel.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The stock awards could potentially dilute existing shareholders' equity, but are intended to incentivize management and improve company performance.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Uri Yablonka, restricted stock, RSU, stock awards, executive compensation, Form 4, reverse stock split